Aurinia to Participate in H.C. Wainwright 26th Annual Global Investment Conference

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Company’s management team will attend the H.C. Wainwright 26th Annual Global Investment Conference in New York City, September 9-11, 2024.

Aurinia management will host one-on-one meetings with investors and will participate in a fireside chat and Q&A session on Tuesday, September 10, at 10:30 AM EST. This session will not include a webcast.

About Aurinia
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy dedicated to the treatment of adult patients with active lupus nephritis. The Company’s head office is in Edmonton, Alberta, and its U.S. commercial office is in Rockville, Maryland. The Company focuses its development efforts globally.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240828651786/en/

Media & Investor Inquiries:
Andrea Christopher,
Corporate Communications & Investor Relations, Aurinia
[email protected]

General Investor Inquiries:
[email protected]

Source: Aurinia Pharmaceuticals Inc.

You May Also Be Interested In

• Aurinia settles patent dispute with Teva over generic voclosporin
• Top Enterprise Architecture Platforms Named 2026 Champions in Info-Tech Research Group's Emotional Footprint Report
• Hangar 1 Publishing.com Announces "Paranormal Duo" for Upcoming Podcast Series